SUMMARY Campath 6, a rat IgG2b monoclonal antibody to the interleukin 2 receptor on activated T cells, was used to treat three patients with active rheumatoid arthritis unresponsive to conventional treatment. Two patients had an excellent response for about three months. There were no significant side effects. The results suggest that activated T cells are of importance in the pathogenesis of rheumatoid arthritis. Although infusions of rat monoclonal antibodies could not be repeated because of the risk of sensitisation, the development of humanised monoclonal antibodies targeted against specific T cell sets would allow repeated courses of treatment to be given.
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Results
All three patients experienced considerable reduction in pain score, morning stiffness, and Ritchie index; C reactive protein and heat distribution index measured with thermography improved in two (Table 1) .
In two patients the benefit persisted for three months, but one patient relapsed within four weeks. Two patients had a febrile reaction during the first infusion, but there were no other side effects. C reactive protein concentrations in both these patients rose dramatically over the first two weeks 428 group.bmj.com on July 8, 2017 -Published by http://ard.bmj.com/ Downloaded from Treatment of RA with monoclonal antibodies 429 despite clinical improvement (Table 1) ; this rise and the fever might have been due to in vivo destruction oftargeted cells. The C reactive protein concentration in the third patient rose later with clinical deterioration. There was no change in lymphocyte numbers or subsets.
Discussion
The clinical improvement after targeting T cells expressing interleukin 2 receptors suggests these cells are of importance in the pathogenesis of rheumatoid arthritis. Raised concentrations of soluble interleukin 2 receptor are found in rheumatoid arthritis and correlate with disease activity.4
This form of treatment is limited by the risk of sensitisation, the development of antibodies to the monoclonal antibodies, and the short term benefit. The use of 'reshaped' monoclonal antibodies, however, using rodent hypervariable and human constant and framework regions would minimise antiglobulin responses and allow effector functions to be selected or tailored as desired. 
